The Heme Degradation Pathway is a Promising Serum Biomarker Source for the Early Detection of Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
One of the remaining challenges in Alzheimer's disease (AD) research is the establishment of biomarkers for early disease detection. As part of a prospective study spanning a period of five years, we have collected serial serum samples from cognitively normal, mild cognitively impaired (MCI), and mild AD participants, including same patient samples before and after cognitive decline. Using mass spectrometry we identified several promising leads for biomarker development, such as prosaposin, phospholipase D1, biliverdin reductase B, and S100 calcium binding protein A7. Selected candidate markers were verified using reverse phase protein microarray assays. Of 15 protein/protein abundance ratios that were significantly altered in sera from subjects with mild AD compared to Normal or MCI subjects, 14 were composed of ratios containing heme oxygenase-1, biliverdin reductase A, or biliverdin reductase B. Moreover, an increase in the protein abundance ratio of matrix metallopeptidase 9/biliverdin reductase differentiated stable MCI subjects from MCI subjects progressing into mild AD before the onset of cognitive decline. These findings strongly implicate the heme degradation pathway as a promising source of protein biomarkers for the early detection of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Elias, J. E., & Gygi, S. P. (2007) · Nature Methods · doi:10.1038/nmeth1019 · Cited by 3,925
Steen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703 · cited 1×
“Insulin signaling is perturbedin AD and the expression of several key components, such as IGF1 and IGF1 receptor, is downregulated [46].”
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L. F., Galasko, D. R., Jutel, M., Karydas, A., et al. (2007) · Nature Medicine · doi:10.1038/nm1653 · Cited by 1,048 · cited 1×
“Therefore it is not surprising that several groups are working on the iden-tification of plasma biomarker candidates for AD [10, 11].”
Evolutionary medicine: from dwarf model systems to healthy centenarians?
Longo, V. D., & Finch, C. E. (2003) · Science · doi:10.1126/science.1077991 · Cited by 575 · cited 1×
“BLVRA is an ERK activator in insulin-like growth factor (IGF) 1 signaling, a pathway that regulates maximum lifespan [44,45].”
Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer’s disease
Atamna, H., & Frey, W. H. (2007) · Mitochondrion · doi:10.1016/j.mito.2007.06.001 · Cited by 278
Serial Susceptibility Weighted MRI Measures Brain Iron and Microbleeds in Dementia
Kirsch, W., McAuley, G., Holshouser, B., Petersen, F., Ayaz, M., Vinters, H. V., Dickson, C., Haacke, E. M., Britt III, W., Larsen, J., et al. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1073 · Cited by 139 · cited 1×
“A detailed description of the subject cohort and classi-fication has been previously described by Kirsch and colleagues [18].”
Self-citation
Cited by
Bioinorganic Chemistry of Alzheimer’s Disease
Kepp, K. P. (2012) · Chemical Reviews · doi:10.1021/cr300009x · Cited by 672
Heme Oxygenase-1 Signaling and Redox Homeostasis in Physiopathological Conditions
Consoli, V., Sorrenti, V., Grosso, S., & Vanella, L. (2021) · Biomolecules · doi:10.3390/biom11040589 · Cited by 284
S100 Proteins in Alzheimer’s Disease
Cristóvão, J. S., & Gomes, C. M. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00463 · Cited by 188
“It is reported that S100A7 is increased in mildly cognitively impaired patients (Mueller et al., 2010) and in the brain and CSF of AD dementia patients (Qin et al.”
BackgroundBarone, E., Di Domenico, F., Mancuso, C., & Butterfield, D. A. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.09.018 · Cited by 127
Haure-Mirande, J.-V., Audrain, M., Fanutza, T., Kim, S. H., Klein, W. L., Glabe, C., Readhead, B., Dudley, J. T., Blitzer, R. D., Wang, M., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1737-3 · Cited by 127
“9) [54] and Nudix motif 19 (Nudt19) (logFC −1.”
Metadata
- Authors
- Mueller, C., Zhou, W., VanMeter, A., Heiby, M., Magaki, S., Ross, M. M., Espina, V., Schrag, M., Dickson, C., Liotta, L. A., & Kirsch, W. M.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2010-01-28
- Volume
- 19
- Issue
- 3
- Pages
- 1081-1091
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1625100636
- Cited by
- 63
- References
- 6
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Heme Degradation Pathway is a Promising Serum Biomarker Source for the Early Detection of Alzheimer's Disease. https://app.cochat.ai/papers/10.3233/jad-2010-1303
- The paper
- Mueller, C., Zhou, W., VanMeter, A., Heiby, M., Magaki, S., Ross, M. M., Espina, V., Schrag, M., Dickson, C., Liotta, L. A., & Kirsch, W. M. (2010). The Heme Degradation Pathway is a Promising Serum Biomarker Source for the Early Detection of Alzheimer's Disease. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-2010-1303
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.